nanoliposomal irinotecan
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peritoneal Cancer
Conditions
Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor, Colorectal Cancer, Gastric Cancer, Primary Peritoneal Carcinoma, Mesothelioma
Trial Timeline
Oct 22, 2019 → Apr 14, 2022
NCT ID
NCT04088786About nanoliposomal irinotecan
nanoliposomal irinotecan is a phase 1 stage product being developed by Ipsen for Peritoneal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04088786. Target conditions include Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04088786 | Phase 1 | Completed |
| NCT02022644 | Phase 1 | Completed |
Competing Products
20 competing products in Peritoneal Cancer